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The oncometabolite 2-hydroxyglutarate activates
the mTOR signalling pathway
Me´lissa Carbonneau1,2, Laurence M. Gagne´3,*, Marie-Eve Lalonde2,*, Marie-Anne Germain2,*, Alena Motorina1,2,
Marie-Christine Guiot4,5, Blandine Secco6,7, Emma E. Vincent8,9, Anthony Tumber10,11, Laura Hulea12,13,
Jonathan Bergeman3, Udo Oppermann10,14, Russell G. Jones8,9, Mathieu Laplante6,7, Ivan Topisirovic12,13,
Kevin Petrecca4, Marc-E´tienne Huot3,15 & Fre´de´rick A. Mallette1,2,16
The identiﬁcation of cancer-associated mutations in the tricarboxylic acid (TCA) cycle
enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights the prevailing notion that
aberrant metabolic function can contribute to carcinogenesis. IDH1/2 normally catalyse the
oxidative decarboxylation of isocitrate into a-ketoglutarate (aKG). In gliomas and acute
myeloid leukaemias, IDH1/2 mutations confer gain-of-function leading to production of the
oncometabolite R-2-hydroxyglutarate (2HG) from aKG. Here we show that generation
of 2HG by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A, an
aKG-dependent enzyme of the Jumonji family of lysine demethylases. Furthermore, KDM4A
associates with the DEP domain-containing mTOR-interacting protein (DEPTOR), a negative
regulator of mTORC1/2. Depletion of KDM4A decreases DEPTOR protein stability.
Our results provide an additional molecular mechanism for the oncogenic activity of mutant
IDH1/2 by revealing an unprecedented link between TCA cycle defects and positive
modulation of mTOR function downstream of the canonical PI3K/AKT/TSC1-2 pathway.
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t is now evident that aberration of normal metabolic function
represents a hallmark of tumorigenesis1. For example,
mutation, deletion or silencing of genes encoding tricarbo-
xylic acid cycle (TCA cycle) proteins, including isocitrate
dehydrogenases 1 and 2 (IDH1/2), are frequent in acute
myeloid leukaemias and brain cancers (WHO grade 2 and 3
astrocytomas, oligodendrogliomas and secondary gliobla-
stomas)2,3. IDH1/2 mutations occur predominantly at arginine
132 for IDH1, and arginine 140 or 172 for IDH2 (refs 2,3), in
each case resulting in a gain of function that promotes conversion
of aKG to 2HG (refs 4,5). These latter metabolites share high
structural similarity, allowing 2HG to bind and inhibit aKG-
dependent enzyme activity including that of the Jumonji lysine
demethylases family and the Ten-eleven translocation (TET)
family of 5-methylcytosine hydroxylases6,7.
Jumonji family members require aKG as co-substrate to
catalyse the removal of methyl moieties on lysine. Conversely,
2HG has been shown to effectively inhibit this family of
enzymes6,7. Jumonji proteins are oxygenases catalysing demethy-
lation of mono-, di- or tri-methylated lysines8,9. To date, more
than 30 Jumonji proteins have been identiﬁed, which carry
different secondary domains in addition to their common JmjC
catalytic domain. These enzymes are classiﬁed into numerous
sub-families according to sequence homology and substrate
speciﬁcity. The KDM4 sub-family comprises four members
(KDM4A-D) which are Fe(II)- and a-ketoglutarate-dependent
enzymes possessing a JmjC catalytic domain8,9. KDM4A-C
display similar structures including JmjN-, tandem PHD-,
and tandem Tudor-domains and each catalyses demethylation of
di- and tri-methylated H3K9 and H3K36. On the other hand,
KDM4D lacks the PHD and tandem Tudor domains and is
speciﬁc for H3K9(me2/3) (refs 10,11). KDM4A is involved in the
regulation of many cellular processes including cell cycle
progression, DNA damage signalling and Ras-induced
senescence12–14.
The mammalian (mechanistic) Target Of Rapamycin (mTOR)
is a serine/threonine kinase belonging to the phosphoinositide
3-kinase (PI3K)-related kinase (PIKK) family. mTOR associates
with either Raptor or Rictor to form distinct complexes, that is,
mTORC1 and mTORC2, respectively, both of which are
regulated by growth factors, amino acids and energy levels15–18.
PRAS40 is recovered within the mTORC1 complex, while mSin1
and Protor1/2 are present in the mTORC2 complex19–22. mLST8
and DEPTOR, an inhibitor of mTOR, are common to both
mTORC1 and mTORC2 (refs 23,24). Among the cellular
processes regulated by mTORC1 are cell growth and
autophagy, while mTORC2 regulates cell survival and
cytoskeleton organisation (for a review, see ref. 25). mTORC1/2
are frequently activated in human cancers via mutation of
upstream negative regulators such as PTEN or TSC2. Following
mTOR activation, DEPTOR is phosphorylated by mTOR, which
in turn leads to phosphorylation of DEPTOR by CK1 (refs 26,27).
These phosphorylation events are recognized by SCFb-TrCP
ubiquitin ligase, resulting in DEPTOR polyubiquitination and
proteolytic degradation26–28. Following its activation by
mTORC1, p70S6K can also phosphorylate DEPTOR, thus
facilitating b-TrCP binding28.
Herein we provide intriguing evidence for a novel oncogenic
mechanism regulated by mutations of IDH1/2, whereby
2HG-induced KDM4A inhibition promotes mTOR activation.
We show that KDM4A speciﬁcally interacts with DEPTOR, a
negative regulator of both mTORC1 and mTORC2. KDM4A
depletion/inactivation results in drastic reduction of DEPTOR
levels, while KDM4A overexpression reduces DEPTOR ubiqui-
tination by b-TrCP1. We also show that 2HG-mediated
inhibition of KDM4A directly affects the stability of DEPTOR,
leading to mTOR activation independently of the PI3K/AKT/
TSC1-2 pathway. This newly revealed PTEN-independent mode
of mTORC1/2 activation via the mutated IDH/2HG/KDM4A/
DEPTOR pathway may provide an additional molecular
mechanism to explain the oncogenic activity of IDH1/2
mutations in glioma and other cancers.
Results
IDH1/2 and PTEN mutations are mutually exclusive. Towards
elucidating the oncogenic properties of mutated IDH1/2, we
analysed The Cancer Genome Atlas (TCGA) and deduced that
mutations in IDH1/2 and PTEN (Phosphatase and TENsin
homologue), an important tumour suppressor frequently
disrupted in many cancers, display mutual exclusivity in
low-grade glioma (Po0.00001; Fisher’s exact test) and
glioblastoma multiforme (P¼ 0.005; Fisher’s exact test; Fig. 1a).
On the other hand, as previously reported29,30, mutations in the
tumour suppressor tp53 often co-occur with IDH1/2 mutations in
low-grade glioma (Po0.0001; Fisher’s exact test) and
glioblastoma multiforme (Po0.00001; Fisher’s exact test)
(Fig. 1a). Thus it appears that major cancer networks can be
strongly inﬂuenced by IDH1/2 gene status. The mutual exclusivity
between IDH1/2 and PTEN mutations suggests that abrogation of
PTEN function might not confer a growth advantage to tumours
carrying IDH1/2 mutations, allowing speculation that IDH1/2
mutations mimic PTEN loss or inactivation. PTEN governs
multiple cellular functions such as survival, growth and energy
metabolism by suppressing the phosphoinositide 3-kinase
(PI3K)/AKT/mTOR pathway. Oncogenic activation of mTOR
stimulates critical processes required for cancer cell survival,
proliferation, angiogenesis and metastasis25. Importantly, even
though no PTEN mutations were observed in IDH1/2-mutated
gliomas, the mTOR pathway is nonetheless frequently activated
in these tumours31.
IDH1/2 mutations and 2HG activate mTOR signalling. The
above considerations prompted us to postulate the existence of a
PTEN-independent mode of mTOR pathway activation by
oncogenic IDH1/2, which might constitute an important deter-
minant in glioma development. We ﬁrst evaluated the possibility
that the mTOR pathway is actually regulated by oncogenic
IDH1/2. Murine embryonic ﬁbroblasts (MEFs) retrovirally
transduced with cancer-associated IDH1R132H or IDH2R172K, but
not with wild-type counterparts, exhibited increased mTORC1
and mTORC2 signalling as highlighted by enhanced phosphor-
ylation of p70S6K, S6 and Rictor, and AKT, respectively (Fig. 1b
and Supplementary Fig. 1a). The extent of mTORC1 stimulation
correlated with intracellular levels of the oncometabolite
R-2-hydroxyglutarate (2HG) produced by mutant IDH1 and
IDH2 (Fig. 1c). Intracellular accumulation of 2HG in mutated
IDH1/2-expressing cells is not associated with decreased levels of
aKG levels (Supplementary Fig. 1b), which has been shown, in
different studies, to either inhibit32 or stimulate33–35 mTOR
activity.
It has been shown that mTOR activity is a major determinant
of cell size36. Therefore, to probe the physiological response to
mutant IDH1/2-mediated activation of mTOR signalling, we
compared the effects of IDH1WT, IDH1R132H, IDH2WT and
IDH2R172K expression in MEFs on cell size using ﬂow cytometry.
Cells expressing mutated IDH1/2 were larger than control
counterparts (Fig. 1d and Supplementary Fig. 1c,d), and this
increase correlated with intracellular levels of 2HG (Fig. 1c).
Moreover, treatment of IDH2R172K-expressing cells with
the mTORC1 inhibitor rapamycin mitigated the effect on cell
size (Fig. 1e). In addition, treatment with rapamycin or the
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mTORC1/2 inhibitor Torin1 abrogated S6 phosphorylation on
serines 240 and 244 in IDH1/2 mutant-expressing cells,
conﬁrming the activation of mTORC1-dependent p70S6K by
2HG-producing mutants (Fig. 1f). Expression of IDH1R132H in
cells treated with AGI-5198, an inhibitor of mutated IDH1
(ref. 37), failed to activate mTORC1 (Supplementary Fig. 1e),
suggesting that oncogenic IDH1-mediated production of 2HG is
responsible for mTOR stimulation.
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Figure 1 | Activation of mTOR signalling by 2HG-producing IDH1/2 gain-of-function mutations. (a) IDH1/2 and PTEN mutations are mutually exclusive
in low-grade gliomas and glioblastomas. Data were obtained from The Cancer Genome Atlas (TCGA). Each vertical lane represents one patient; green lines
depict the presence of a mutation. Statistical analysis was performed using the Fisher’s exact test. (b) mTOR pathway activation in MEFs p53 / cells
expressing wt versus mutant IDH. Flag-tagged IDH was retrovirally transduced into MEFs p53 / cells, and whole-cell lysates were harvested at 9 days
post selection. Asterisk denotes a nonspeciﬁc band recognized by the antibody. (c) Intracellular accumulation of 2HG on IDH1/2 mutant expression as in b.
2HG levels were normalized against glutamate levels. Asterisks denote a statistical difference between IDH1/2 mutated cells and empty vector cells, two-
sided t-test Po0.0001 (graph represents three independent experiments). Error bars represent standard deviation. (d) Increased cell size associated with
mutated IDH1/2 expression. FSC measurement in FACS analysis demonstrates the shift in cell size in MEFs p53 / cells expressing IDH1R123H (green line)
or IDH2R172K (blue line) compared with empty vector-infected cells (black line). A total 250,000 cells were counted for each condition and graph is
representative of four independent experiments. (e) Inhibition of mTORC1 rescues the increased cell size in IDH2R172K mutant cells. MEFs p53 / cells
expressing IDH2R172K or empty vector were treated with 25 nM rapamycin for 16 h before FACS analysis. A total 250,000 cells were counted for each
condition. (f) Rapamycin or Torin1 treatment prevents mTORC1 activation in cells expressing IDH1/2 mutants. MEFs p53 / cells expressing IDH1/2
mutants were treated with 100 nM rapamycin or 250nM Torin1 for 24 h and whole-cell lysates blotted for markers of mTORC1 activation. (g) 2HG
stimulates the mTOR pathway. MEFs p53 / were treated with 2mM of octyl-2HG for 4 h, and whole-cell extracts analysed by western blot. (h) Octyl-
2HG treatment increases cell size. MEFs p53 / cells were treated with 1mM octyl-2HG for 8 h before FCS analysis by FACS. A total 25,000 cells were
counted for each condition and graph is representative of two independent experiments.
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To directly evaluate whether 2HG is responsible for activation
of mTORC1/2, we synthesized cell permeable 1-octyl-D-2-
hydroxyglutarate (octyl-2HG) (Supplementary Fig. 1f)38. Treat-
ment of cells with octyl-2HG led to activation of mTORC1/2, as
illustrated by increased phosphorylation of p70S6K, S6, Rictor
and AKT in both MEFs and HeLa cells (Fig. 1g and
Supplementary Fig. 1g) in a time- and dose-dependent
fashion (Supplementary Fig. 1h,i) compared with the control.
Furthermore, treatment with octyl-2HG caused a relative increase
in cell size (Fig. 1h), consistent with activation of mTOR by 2HG.
2HG-mediated effects on phosphorylation of mTORC1 substrates
and cell size were attenuated by rapamycin (Supplementary
Fig. 1j,k), and effect on mTORC2 activity inhibited by Torin1
(Supplementary Fig. 1l). Taken together, our results demonstrate
that IDH1/2 mutations engender an increase in 2HG levels that
stimulate mTOR signalling via both mTORC1 and mTORC2.
KDM4A modulates mTOR activity. Previous studies showed
that mutated IDH1/2-stimulated 2HG production inhibits the
activity of aKG-dependent enzymes including (i) the Jumonji
family of Fe(II)-dependent oxygenases comprising lysine deme-
thylases and (ii) the TET family of 5-methylcytosine hydro-
xylases6,7. To evaluate the possibility that one or more enzymes
among these families is/are responsible for regulation of
mTORC1 activity, we performed a targeted short interfering
RNA (siRNA) screen in HeLa cells using S6 phosphorylation on
serines 240 and 244 as a readout of mTOR activity. Among the
aKG-dependent enzymes tested, depletion of KDM4A showed
the most potent increase in S6 phosphorylation (Fig. 2a). KDM4A
is an Fe(II)- and aKG-dependent enzyme possessing a JmjC
catalytic domain8,9, as well as tandem PHD- and tandem Tudor-
domains which are thought to associate with methylated
chromatin residues. KDM4A catalyses demethylation of di- and
tri-methylated H3K9 and H3K36 (refs 9,39–41), and modulates
multiple cellular processes including the DNA damage
response13, cellular senescence14,42,43, transcription40,44, DNA
replication12,45 and innate immunity46. Knockdown of KDM4A
using three different short hairpin RNAs (shRNAs) led to
increased phosphorylation of the mTORC1 substrates
p70S6KT389 and 4E-BP1S65, and of the mTORC2 substrate
AKTS473 (Fig. 2b), thus validating our siRNA screening approach.
As AKT modulates cell survival and depletion of KDM4A leads to
AKT activation (Fig. 2b), we determined the function of KDM4A
in cell survival on metabolic stress. KDM4A knockdown
prevented cleavage of caspase-3 and PARP, two indicators of
apoptosis, following serum withdrawal (Fig. 2c). Moreover
KDM4A-depleted cells were larger than cells treated with
siGFP, and treatment with the mTORC1 inhibitor rapamycin
abrogated this phenotype (Fig. 2d). We emphasize that the entire
KDM4 family shares common substrates; nonetheless KDM4A
was the sole family member to inﬂuence mTORC1 activity, as
depletion of KDM4B-D had no impact on phosphorylation of
4E-BP1, S6 and Rictor (Supplementary Fig. 2a,b). KDM4A is
profoundly inhibited by 2HG, exhibiting an IC50 of 2.1 mM
(Fig. 2e) as determined by RapidFire mass spectrometry. 2HG
failed to further increase mTORC1 activity in KDM4A-depleted
cells (Fig. 2f), suggesting that inhibition of KDM4A by 2HG-
producing mutated IDH1/2 is responsible for mTORC1/2
activation.
KDM4A interacts with mTORC1/2. To elucidate the molecular
mechanism involved in the regulation of mTOR kinase activity by
KDM4A, we evaluated whether the latter transcriptionally mod-
ulates either PTEN/AKT/mTOR pathway regulators or
mTORC1/2 complex components. Depletion of KDM4A in HeLa
cells revealed minor or no signiﬁcant changes in mRNA levels for
either PTEN or tuberous sclerosis 1/2 (TSC1/2) (Fig. 3a). TSC1/2
is a GTPase-activating protein complex that maintains Rheb (Ras
homologue enriched in brain) in an inactive form, thereby
causing mTOR inhibition47–49. In addition, mRNA levels of
RHEB, mTOR, DEPTOR or the upstream activating kinase PDK1
were at most very modestly changed following KDM4A depletion
(Fig. 3a). Similar observations were made at the protein level for
KDM4A-depleted cells, where expression of PTEN, TSC2,
mTOR, Rictor and components of the amino acid signalling
arm (that is, Rag and LAMTOR) remained essentially unaltered
(Supplementary Fig. 2c,d). Interestingly, KDM4A knockdown
had no impact on phosphorylation of AKT at threonine 308, a
site phosphorylated by PDK1 after PI3K activation, suggesting
that activation of mTORC1 occurs downstream PDK1/AKT
(Supplementary Fig. 2c). This was further conﬁrmed by our result
showing that pharmacological PI3K inhibition using CAL-101
did not block activation of mTORC2 upon depletion of KDM4A,
as revealed by increased phosphorylation of AKTS473
(Supplementary Fig. 2e). Furthermore, knockdown of KDM4A
in rapamycin-treated cells still caused activation of mTORC2,
implying mTORC1-independent modulation of mTORC2 by
KDM4A (Supplementary Fig. 2e).
Since the control exerted by KDM4A on mTOR activity seems to
occur downstream of PTEN–PDK1–AKT–TSC1/2, we investigated
whether KDM4A might physically interact with the mTORC1/2
complexes. Consistent with this possibility, KDM4A co-immuno-
precipitated numerous members of mTORC1 and mTORC2
including mTOR, Raptor, Rictor, mSin1 and DEPTOR (Fig. 3b
and Supplementary Fig. 3a–c). We then qualitatively compared the
amount of mTORC1/2 components interacting with mTOR or
KDM4A. Flag-tagged KDM4Amodestly interacted with mSin1 and
Raptor when compared with the amount co-immunoprecipitated
with mTOR. On the other hand, both KDM4A and mTOR
immunoprecipitated similar amounts of DEPTOR (Fig. 3c and
Supplementary Fig. 3d), suggesting that DEPTOR might represent
the major mTORC1/2 component interacting with KDM4A. We
conﬁrmed the interaction between DEPTOR and KDM4A in cells
co-expressing the exogenous tagged proteins (Fig. 3d). Moreover,
ectopic Flag-tagged DEPTOR co-immunoprecipitated endogenous
KDM4A (Fig. 3e) and this interaction appeared to be mediated by
the DEPTOR PDZ domain (Fig. 3f). Individual depletion of mTOR
or mSin1 did not alter the binding of KDM4A and DEPTOR
(Supplementary Fig. 3e,f), supporting our hypothesis that
DEPTOR is the major mTORC1/2 component interacting with
KDM4A. Endogenous KDM4A and DEPTOR are also associated
in 293E (Fig. 3g), HeLa (Supplementary Fig. 3g), as well as in
glioma-related central nervous system-derived cells, that is,
immortalized normal human astrocytes (NHAs; Fig. 3h). Surpris-
ingly, endogenous KDM4B also interacted with DEPTOR
(Supplementary Fig. 3h), but was unable to modulate mTOR
activity (Supplementary Fig. 2a). Recombinant KDM4A and
DEPTOR proteins puriﬁed from E.coli failed to interact (Supple-
mentary Fig. 3i), suggesting that KDM4A–DEPTOR interaction
might be indirect, or requires either post-translational modiﬁca-
tions absent in bacteria or conformational changes in DEPTOR
occuring during its association with mTORC1 or mTORC2. We
performed a fractionation assay to conﬁrm that KDM4A and
DEPTOR localize to the same sub-cellular compartments. While
DEPTOR is mostly cytoplasmic, KDM4A was present in both the
nucleus and cytoplasm (Supplementary Fig. 4a,b).
KDM4A stabilizes DEPTOR. The stability of DEPTOR, an
endogenous negative regulator of mTOR activity24, is tightly
regulated in response to growth signals via mTOR in conjunction
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with the SCF(bTrCP) E3 ubiquitin ligase complex26–28. We
sought to determine the impact of KDM4A on DEPTOR protein
levels. KDM4A knockdown led to a signiﬁcant decrease in both
DEPTOR protein levels (Fig. 4a) and half-life after serum
stimulation (Supplementary Fig. 5a-b). Transient expression
of wild-type KDM4A or tandem Tudor-disrupted
KDM4AD939R, but not of catalytically inactive KDM4AH188A,
in KDM4A-depleted cells partially restored DEPTOR levels
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Figure 2 | Targeted-siRNA screen reveals KDM4A as an a-KG-dependent enzyme modulating mTOR activity. (a) siRNA screen of aKG-dependent
enzymes for the involvement in mTOR signalling in HeLa cells. The experiments were performed in triplicate and the results of all experiments were plotted.
The levels of phosphorylated S6 on serines 240/244 were normalized to total S6 protein. (b) KDM4A knockdown increases mTORC1/2 signalling.
Depletion of KDM4A by lentiviral infection in HeLa cells using three different shRNAs. Whole-cell lysates were blotted for mTORC1/2 activation.
(c) Depletion of KDM4A protects against apoptosis induced by serum deprivation. HeLa cells expressing a control shRNA or shRNAs targeting KDM4A
were grown in media containing the indicated concentrations of serum for 24 h. Cell lysates were then analysed by western blotting. (d) KDM4A depletion
increases cell size in an mTORC1-dependent manner. MEFs p53 / were treated with siKDM4A and, where indicated, with DMSO or 25 nM rapamycin,
for 16 h before FSC measurements by FACS. A total 200,000 cells were counted for each condition. (e) Dose-dependent inhibition of KDM4A by R-2HG in
in vitro demethylation assay (graph represents two independent experiments). (f) 2HG does not further stimulate mTORC1 in KDM4A-depleted HeLa cells.
HeLa cells transfected with siGFP or siKDM4A were serum starved for 16 h before stimulation with 2mM octyl-2HG for 4 h.
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(Supplementary Fig. 5c,d). This partial rescue might reﬂect
reduced transfection efﬁciency (40–50%) of lentiviral-transduced
cells under our experimental conditions. It is also possible that
the transient nature of KDM4A re-introduction may not allow
enough time for complete restoration of DEPTOR levels. We
cannot exclude, however, that a portion of the effects we observed
on DEPTOR levels are independent of KDM4A and maybe due to
shRNA off-targeting effects. In addition, overexpression of
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Figure 3 | KDM4A interacts with the mTORC1/2 complex. (a) Relative mRNA levels of negative and positive regulators of the PTEN/AKT/mTOR
pathway following KDM4A depletion. Quantiﬁcations of mRNAs by RT–qPCR were normalized against b-actin (ActB) mRNA. Asterisks denote a statistical
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represent standard deviation. (b) Co-immunoprecipitation of endogenous mTORC1/2 complex members with Flag-KDM4A in 293T transfected cells.
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wild-type KDM4A signiﬁcantly abrogated in vivo ubiquitination
of DEPTOR by bTrCP1 (Fig. 4b,c); moreover, this reduction
was dependent on the catalytic activity of the demethylase,
but not on its chromatin-binding ability, since overexpression
of the KDM4AD939R Tudor domain mutant, but not of the
KDM4AH188A catalytic dead mutant, decreased DEPTOR poly-
ubiquitination (Fig. 4b,c). In addition, KDM4A interacted with
b-TrCP ubiquitin ligases (Supplementary Fig. 5e). Consistent
with our ﬁnding that inhibition of KDM4A decreased DEPTOR
protein levels, expression of the 2HG-producing IDH1R132H
mutant also caused such a reduction (Fig. 4d). Treatment of
human ﬁbrosarcoma HT1080 cells bearing a heterozygous
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IDH1R132C mutation with the mutated-IDH1-speciﬁc inhibitor
AGI-5198 (ref. 37) caused a marked decrease in mTORC1/2
activity. Moreover this was rescued upon KDM4A depletion
(Fig. 4e and Supplementary Fig. 5f,g), showing that 2HG-
mediated inhibition of KDM4A is indeed responsible for
activation of mTOR. Our data raise the intriguing possibility
that cancer therapeutic regimens designed to inhibit mutated
IDH1/2 would be expected to reduce oncogenic mTOR activity.
IDH1 mutation and 2HG regulate mTOR in human astrocytes.
To evaluate the impact of IDH mutations on mTOR activation in
a more physiological setting, we ﬁrst retrovirally transduced
immortalized NHAs with empty vector, wild-type IDH1 or
IDH1R132H. NHAs expressing mutant IDH1 displayed higher
levels of p-AKTS473 (Fig. 4f) associated with increased accumu-
lation of intracellular 2HG (Fig. 4g), but did not manifest
decreased aKG (Supplementary Fig. 5h). In addition, treatment of
NHAs with octyl-2HG led to activation of mTORC1 and
mTORC2, as indicated by increased p-S6S240/244 and p-AKTS473,
respectively (Fig. 4h). Finally, octyl-2HG decreased DEPTOR
levels in NHA, as compared with control (Supplementary Fig. 5i).
We then asked whether oncogenic IDH1 might be associated
with markers of mTOR activation in human brain tumours.
Immunohistochemistry analysis of IDH1R132H-mutated human-
grade 2/3 astrocytoma samples revealed an increase in S6
phosphorylation on serines 240/244 (Fig. 4i). However, while 20
to 40% of the tumour cells from wild-type IDH1/2 astrocytomas
showed strong staining for p-AKTT308, the upstream activator of
mTORC1, less than 2% of IDH1R132H-mutated astrocytomas
stained positively for p-AKTT308 (Fig. 4i). This suggests that
activation of mTORC1 occurs downstream of the PI3K–PDK1–
AKT cascade in tumours harbouring IDH1 mutations, supporting
the notion that 2HG-mediated inhibition of KDM4A affects the
stability of DEPTOR leading to mTOR activation independently of
the PI3K/AKT/TSC1-2 pathway (Fig. 5).
Discussion
IDH mutations, frequently observed in brain tumours and
leukaemia, lead to production of the oncometabolite 2HG,
which in turn causes cell differentiation defects by impairing
histone demethylation38. In addition, reversible inhibition of the
50-methylcytosine hydroxylase TET2 by 2HG causes profound
epigenetic changes contributing to transformation50,51. Herein we
describe for the ﬁrst time that oncogenic IDH and subsequent
production of 2HG activate mTOR signalling. Either expression
of mutated IDH1/2 or treatment with 2HG engendered activation
of both mTORC1 and mTORC2 and, as a consequence, cell size
increase. We note that the mTORC1 inhibitor rapamycin
signiﬁcantly, but only partially, decreased cell size of
IDH2R172K-expressing cells. In mammalian systems, control of
cell size by mTOR is mediated by both p70S6K and 4E-BP/
eIF4E36. As these latter factors display differential sensitivity to
rapamycin52, recovery of 4E-BP1 phosphorylation in rapamycin-
treated IDH2R172K cells might explain the observed partial rescue
of cell size (Fig. 1e).
Since 2HG constitutes an inhibitor of a-ketoglutarate-depen-
dent enzymes, we used a targeted siRNA screen against these
enzymes to identify KDM4A as a novel regulator of mTOR.
Furthermore, our data indicate that KDM4A controls mTOR
through modulation of DEPTOR stability. Indeed, KDM4A
catalytic activity is essential for decreasing b-TrCP1-dependent
poly-ubiquitination of DEPTOR (Fig. 4b,c) thereby promoting
DEPTOR protein stability (Supplementary Fig. 5c). Further
investigation will be required to identify the substrate(s)
of KDM4A-mediated demethylation involved in controlling
DEPTOR stability.
Ampliﬁcation of KDM4A gene copy number, or of its mRNA
expression, has been observed in various cancers. Such upregula-
tion of KDM4A has been reported to promote site-speciﬁc
genomic ampliﬁcation45 or hinder p53 activation and sene-
scence14. Conversely, genomic loss of KMD4A and concomitant
decrease in mRNA levels has also been reported in multiple
tumour types (Supplementary Fig. 6a–j)45, particularly bladder
cancer where KDM4A downregulation correlates with tumour
progression53. Our own results suggest that decreased KDM4A
expression could contribute to mTOR activation during cancer
development, suggesting that this demethylase could act as a
context-dependent oncogene.
Recent evidence demonstrates that mTORC1 controls mito-
chondrial activity54 and stimulates metabolism of glutamine55, an
amino acid catabolized into aKG, suggesting that mTOR
modulates the TCA cycle. Here we provide evidence that TCA
cycle defects can lead to aberrant activation of mTOR kinase.
Indeed our data show that KDM4A associates with DEPTOR, and
that 2HG-mediated inhibition of KDM4A in IDH1/2-mutated
cells impacts DEPTOR protein stability leading to mTOR
activation (Fig. 5). On the other hand, it has been reported that
2HG inhibits ATP synthase and mTOR activity in cell lines
wherein mTOR is chronically hyperactivated due to the loss
of PTEN activity or other causes56. Under such conditions,
2HG-mediated inhibition of ATP synthase might alter the
ATP/ADP ratio leading to a decrease in mTOR activity. As a
possible explanation for this controversy, we emphasize that our
genomic analysis of human gliomas and glioblastomas revealed
that IDH and PTEN mutations are mutually exclusive.
In addition, our data show that 2HG stimulates mTORC1/2
activity in numerous cell lines where mTOR is not hyperactivated
by abrogation of PTEN. Furthermore, mTOR signalling is readily
observed in clinical samples of IDH1-mutated gliomas. This
clearly suggests that the effects of 2HG on mTOR signalling rely
on the integrity of upstream signalling pathways.
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Figure 5 | Non-canonical regulation of mTOR activity by 2HG-mediated
inhibition of KDM4A. Simpliﬁed schematic model for mTOR activation
following KDM4A inhibition by IDH1/2 gain-of-function mutations.
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The novel PTEN-independent mode of mTORC1/2 activation
via mutated IDH/2HG/KDM4A/DEPTOR revealed here may
provide an additional molecular explanation for the oncogenic
activity of IDH1/2 mutation in brain cancer. This would indicate
a potential therapeutic strategy to target oncogenic mTOR
signalling in cancers harbouring IDH1/2 mutations.
Methods
Cell culture. HEK293T, HeLa, HT1080 and 293E were obtained from the
American Type Culture Collection (ATCC), p53 / MEFs were obtained from
Dr Gerardo Ferbeyre and previously described57, and normal human astrocytes
immortalized by hTERT (NHA-hTERT) were kindly provided by Dr Nada Jabado.
All the cell lines were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone), 1% sodium
pyruvate (Gibco) and 1% penicillin/streptomycin (Gibco). Mycoplasma
contamination check has been carried out for all cancer cell lines.
Plasmids and transfections. Cells were transfected with 10 mg of DNA using
30mg of linear polyethylenimine. The following vectors were used: pcDNA3.1 Flag-
eYFP, pLPC Flag-KDM4A, pCMV-Sport6-Flag-mTOR, pMSCV HA-DEPTOR,
pDEST myc-KDM4A wild type or mutants (H188A and D939R), pcDNA3 Myc-b-
TrCP1 (Addgene plasmid #20718; gift from Dr Yue Xiong) and pcDNA3 HA-Ub.
The following plasmids, pRK5 Myc-mTOR (Addgene plasmid #1861), pRK5 Myc-
Raptor (Addgene plasmid #1859), pRK5 Myc-Rictor (Addgene plasmid #11367),
pRK5 Flag-DEPTOR (Addgene plasmid #21334), pRK5 Flag-DEPTOR DEP
domains (Addgene plasmid #21700) and pRK5 Flag-DEPTOR PDZ domain
(Addgene plasmid #21701) were gifts from Dr David Sabatini.
Lentiviral and retroviral infections. Lentiviral particles were generated by
transfecting 293T cells using 5 mg of shRNA plasmid, 3.75mg of psPAX2 packaging
plasmid and 1.25 mg pMD2.G envelope plasmid. Media was changed 24 h after
transfection and lentiviral particles were harvested 24 h later. Viral supernatant was
ﬁltered through 0.45 mm ﬁlters and supplemented with 8 mgml 1 polybrene and
10% FBS. Viruses were titrated using limiting dilution in HeLa cells and the same
MOI was used for each condition. The following plasmids were used: pLKO.1-
sh_Control, pLKO.1-sh_KDM4A#3 (RHS3979-201745071, Dharmacon), pLKO.1-
sh_KDM4A#5 (RHS3979-201745073, Dharmacon), pLKO.1-sh_KDM4A#7
(RHS3979-201745075, Dharmacon), pLKO.1-sh_mTOR#53 (TRCN0000195453,
Sigma), pLKO.1-sh_mTOR#84 (TRCN0000039784, Sigma), pLKO.1-sh_mSin1#1
(13483, Addgene) and pLKO.1-sh_mSin1#2 (13484, Addgene).
Retroviruses were produced by transfecting packaging cells (Phoenix) with
10mg of DNA using 30mg of polyethylenimine. Media was changed 24 h later and
viral supernatant harvested at 48 and 56 h post-transfection. Viral supernatants
were ﬁltered through 0.45mm ﬁlters and supplemented with 8 mgml 1 polybrene
and 10% FBS. Media were changed 16 h after infection. Retroviral plasmids pLPCX
IDH1WT Flag, pLPCX IDH1R132H Flag, pLPCX IDH2WT Flag and pLPCX
IDH2R172K Flag are described in ref. 58. The pLXSN IDH1WT Flag and pLXSN
IDH1R132H Flag were generated by PCR of the IDH1 genes (forward primer with
EcoR1 site : 50-TAGAATTCATGTCCAAAAAAATCAGTGG-30 , reverse primer
with Xho1 site and Flag tag : 50-ACCTCGAGTTACTTGTCATCGTCATCCTT
GTAATCCATAAGTTTGGCCTG-30). PCR products were inserted into the
EcoRI- and XhoI-linearized pLXSN vector.
FACS-cell size determination. The cells were trypsinized and resuspended in
phosphate-buffered saline (PBS) containing 2% FBS. Forward-scatter measurement
(FSC) intensity was measured using BD FACSCalibur (BD Biosciences) and
analysed with BD CellQuest Pro software (BD Biosciences). For each experiment
1,00,000–2,00,000 cells were analysed, except for cells treated with 2HG where
10,000–25,000 cells were used.
Immunoblots and antibodies. The cells were lysed in 10mM Tris (pH 7.4),
120mM NaCl, 0.5% Triton with protease inhibitor mix (cOmplete, Roche) and
phosphatase inhibitors (PhosSTOP, Roche) and sonicated for 3 10 s. After
centrifugation at 15,000g for 10min, proteins were separated on SDS–PAGE and
transferred to nitrocellulose or PVDF membranes (Bio-Rad). Primary antibodies
used were anti-Flag (M2, Sigma, 1:5,000), anti-HA.11 (16B12, Covance, 1:1,000),
anti-Myc (9E10, Sigma, 1:1,000), anti-a-Tubulin (B-5-1-2, Sigma, 1:10,000), anti-
KDM4A (NB110-40585, Novus Biologicals, 1:1,000) and (N154/32, NeuroMab,
1:1,000), anti-mTOR (2972, Cell Signaling, 1:1,000) (7C10, Cell Signaling, 1:1,000),
anti-DEPTOR (ABS222, Millipore, 1:1,000), anti-DEPTOR (D9F5, Cell Signaling,
1:500), anti-DEPTOR (NBP1-49674, Novus Biologicals, 1:1,000), anti-GbL
(PA5-17442, Thermo Scientiﬁc, 1:1,000), anti-Raptor (24C12, Cell Signaling,
1:1,000), anti-phospho-Raptor S792 (2083, Cell Signaling, 1:1,000), anti-PRAS40
(PA5-17184, Thermo Scientiﬁc, 1:1,000), anti-Rictor (53A2, Cell Signaling,
1:1,000), anti-phospho-RictorT1135 (D30A3, Cell Signaling, 1:1,000), anti-mSin1
(07-2276, Millipore, 1:1,000), anti-Protor2 (D19A5, Cell Signaling, 1:1,000),
anti-PTEN (A2B1, Santa Cruz, 1:1,000), anti-TSC2 (T.309-0 Thermo Scientiﬁc,
1:1,000), anti-RagA (D8B5, Cell Signaling, 1:1,000), anti-RagB (D18F3, Cell
Signaling, 1:1,000), anti-RagC (D31G9, Cell Signaling, 1:1,000), anti-RagD
(4470, Cell Signaling, 1:1,000), anti-LAMTOR1 (D11H6, Cell Signaling, 1:1,000),
anti-LAMTOR2 (D7C10, Cell Signaling, 1:1,000), anti-LAMTOR3 (D38G5, Cell
Signaling, 1:1,000), anti-p70S6K (9202, Cell Signaling, 1:1,000), anti-phospho-
p70S6KT389 (108D2, Cell Signaling, 1:1,000), anti-4E-BP1 (53H11, Cell Signaling,
1:1,000), anti-phospho-4E-BP1S65 (9451, Cell Signaling, 1:1,000), anti-S6 (54D2,
Cell Signaling, 1:1,000), anti-phospho-S6S240/244 (5364 and 2215, Cell Signaling,
1:1,000), anti-AKT PH domain (05-591, Millipore, 1:1,000), anti-phospho-AKTS473
(9271, Cell Signaling, 1:1,000) (D9E, Cell Signaling, 1:1,000), anti-phospho-
AKTT308 (C31E5E, Cell Signaling, 1:1,000), anti-PARP (9542, Cell Signaling,
1:1,000), anti-Caspase 3 (9662, Cell Signaling, 1:1,000), anti-actin (D6A8, Cell
Signaling, 1:2,000) and anti-GAPDH (D16H11, Cell Signaling, 1:2,000). Scans of
ECL and/or X-ray ﬁlms showing whole membranes are presented in
Supplementary Fig. 7.
Immunoprecipitations. The cells were lysed in 1ml of lysis buffer (0.3% CHAPS,
50mM Hepes, 120mM NaCl, 2mM EDTA with protease inhibitor mix and
phosphatase inhibitors (Roche)) and sonicated three times for 10 s each (except for
Fig. 3f, for which samples were not sonicated to conﬁrm that the interaction
between KDM4A and DEPTOR occurred prior sonication). After centrifugation at
15,000g for 10min, the supernatant was incubated for 2 h at 4 C with 20ml of Flag
M2 agarose beads (Sigma). Immunoprecipitates were washed three times with lysis
buffer containing 150mM NaCl and twice with TBS before elution in Laemmli
buffer.
For qualitative comparison of IP performed in CHAPS and Triton
(Supplementary Fig. 3d), the cells were lysed in lysis buffer (40mM Hepes pH 7.5,
120mM NaCl, 1mM EDTA with protease inhibitor mix Roche) containing either
0.25% CHAPS or 1% triton. The cells were then sonicated three times for 10 s each
before centrifugation at 15,000g for 10min. The supernatants were incubated for
1 h at 4 C with 20 ml of Flag M2 agarose beads (Sigma). The immunoprecipitates
were washed ﬁve times with lysis buffer and eluted in Laemmli buffer.
For HA-Ub IP, the cells were serum starved for 24 h followed by 30min serum
stimulation (10%) before addition of lysis buffer A (20mM Tris pH 7.5, 1% Triton,
150mM NaCl, 1mM EDTA, 1mM EGTA, 20mM N-ethylmaleimide with protease
inhibitor mix and phosphatase inhibitors (Roche)). Sample were sonicated three
times for 10 s each and immunoprecipitated with 20 ml of HA agarose beads
(Sigma) for 2 h at 4 C. The immunoprecipitates were washed three times with lysis
buffer A before elution in Laemmli buffer.
For endogenous KDM4A IP, B2 108 cells (NHAs, HeLa or 293E) were
resuspended in 5ml of lysis buffer A with 0,5% triton. Extracts were prepared
as described above and were pre-cleared for 1 h with 20 ml protA/G beads
(Cell Signaling). Immunoprecipitations were performed with 12 mg of NO66
antibody (negative control, SCG consortium, ABC058-F03), KDM4A antibody
(p014, SCG consortium) or KDM4B antibody (SCG consortium) overnight at 4 C.
60 ml of M-280 streptavidin-coated dynabeads (Life Technologies) were added to
each sample and incubated for 1 h at 4 C. The beads were washed three times with
lysis buffer A before elution in Laemmli buffer.
Production of recombinant proteins. The GST-DEPTOR (pGEX 5X3),
His-KDM4A(aa 1-562) and His-KDM4A(aa 563-1064) (pDest17) were expressed
in BL21 bacteria grown in LB. After induction with IPTG (0.2mM) for 16 h at
20 C, bacteria were harvested by centrifugation and lysed by sonication. The
GST-fusion protein was puriﬁed on glutathione agarose beads (Sigma) and the
His-fusion protein were puriﬁed with Ni-NTA agarose (Qiagen). The His-fusion
proteins were eluted off the beads using 200mM imidazole buffer and dialysed
overnight against PBS, followed by concentration on Amicon columns (Millipore).
GST pull-down assays. For GST pull-downs, 1 mg of puriﬁed GST-DEPTOR
recombinant protein was incubated for 2 h at 4 C with 500 ng of His-KDM4A
(aa 1–562) or (aa 563–1064) recombinant protein in GST pull-down buffer
(25mM HEPES pH7.5, 250mM KCl, 0,1% NP-40, 10% glycerol, 100 mgml 1
BSA). The beads were then washed with GST pull-down buffer four times and
eluted in Laemmli buffer 2 .
Metabolite extraction and quantiﬁcation of 2HG. Quantiﬁcation of citric acid
cycle (CAC) organic acid intermediates was carried out at the Goodman Cancer
Research Center metabolomics core facility (McGill University, Montreal, QC,
Canada). Following cellular extraction and either keto-acid reduction or methox-
imation, GC/MS data were collected and analysed as described in detail59,60 except
that 4 ml of the deuterated CAC standard mix was added due to the high level
of 2-hydroxyglutaric acid in mutant IDH1/2-expressing cells. Resulting levels of
CAC intermediates were normalized against cell number.
Synthesis of 1-octyl-D-2-hydroxyglutarate. Synthesis of 1-octyl-D-2-hydro-
xyglutarate was performed as previously described38. Brieﬂy, commercial R(-)-
tetrahydro-5-oxofuran-2-carboxylic acid (910mg, 7mmol) was dissolved in water
(1ml), cooled to 0 C and treated with 1N KOH (14.7ml, 14.7mmol). After
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stirring, the solution was dessicated under reduced pressure, co-evaporated with
EtOH and dried. The white salt obtained was partially dissolved in triﬂuoroactic
anhydride (50ml) and the solution evaporated under reduced pressure. Anhydrous
tetrahydrofuran (45ml) was then used to dry and dissolve the residue, and octanol
(2.3ml, 14.7mmol) was added to the resulting solution. After stirring overnight,
water was added to quench the reaction and the mixture extracted with EtOAc. The
extracts were combined, dried over MgSO4, concentrated and puriﬁed by ﬂash
chromatography eluting with Hexanes-EtOAc 3:1 to 1:1 giving 1-octyl-D-2-
hydroxyglutarate (70mg, 7 %) as an oil. 1H NMR (CD3OD) d: 4.19 (m, 1H), 4.15
(m, 2H), 2.51–2.36 (m, 2H), 2.12–2.04 (m, 1H), 1.94–1.85 (m, 1H), 1.70–1.63
(m, 2H), 1.40–1.31 (m, 10H), 0.90 (t, 3H, J¼ 6.8Hz); MS (APCI neg) 259.05
[M-H]-.
siRNA screen targeting aKG-dependent oxygenases. HeLa cells were trans-
fected using Lipofectamine RNAiMAX (Invitrogen) using reverse transfection
protocol supplied by the manufacturer. Brieﬂy, 20 nM siRNA duplexes and 10 ml
RNAiMAX lipofectamine (Invitrogen) were diluted in 1ml OPTI-MEM (Invitro-
gen) in 6mm plates and incubated for 15min before adding 600,000 cells per plate.
Three days following the transfection, the cells were lysed in 10mM Tris-HCl,
100mM NaCl, 0.5% Triton X-100, pH 7.6 with protease inhibitor mix and
phosphatase inhibitors (Roche), sonicated three times for 10 s, then centrifuged for
10min at 10,000g. The supernatants were then analysed by western blotting for
total S6 or phospho-S6S240/244, and quantiﬁcation of band intensity was performed
using ImageJ. All siRNAs were purchased from ThermoScientiﬁc (Dharmacon).
For a complete list of siRNAs, see Supplementary Table 1.
Immunoﬂuorescence. Cells were ﬁxed with 4% paraformaldehyde in PBS for
5min at room temperature and permeabilized with 1% Triton X-100 in PBS for
5min at room temperature. Fluorescent visualization of KDM4A was performed
using pAb anti-KDM4A antibody (1:100, NB110-40585; Novus Biologicals)
coupled with an Alexa Fluor 488 Goat Anti-Rabbit IgG (Hþ L) secondary antibody
(catalogue # 4412, Cell Signaling, 1:1,000). Polymerized actin was visualized using
CFt568 phalloidin (catalogue # 00044-300U; Biotium). DNA was stained with
40 ,60-diamidino-2-phenylindole (DAPI). Immunoﬂuorescent images were captured
using a  60 lens (1.42 NA, splan APO), mounted on an FV1000 confocal laser
scanning microscope driven by FluoView software (Olympus). Image acquisition
was performed at room temperature, the brightness/contrast tool in FluoView
software (Olympus) was used to process images and montages were made using
Photoshop CS6 (Adobe).
Cell fractionation. The harvested cells were suspended in cold extraction buffer
(10mM Hepes (pH 7,4), 5mM MgCl2, 320mM sucrose and 1% Triton X-100),
agitated for 10 s and incubated on ice for 10min. The cells were centrifuged at
2,000g and the supernatant (cytoplasmic fraction) collected while the pellet
(nuclear fraction) was washed two times with 10mM Hepes (pH 7,4) containing
5mM MgCl2 and 320mM sucrose.
Quantitative real-time PCR. Total RNA was isolated using Trizol (Invitrogen)
according to the manufacturer’s protocol. The High Capacity cDNA Reverse
Transcription Kit was used with random primers (Applied Biosystems) to reverse
transcribe 2 mg of total RNA in a ﬁnal volume of 20 ml. GAPDH (glyceraldehyde-
3-phosphate dehydrogenase), HPRT1 (hypoxanthine guanine phosphoribosyl
transferase) and ACTB (Beta-actin) were used as endogenous controls and their
gene expression levels determined using pre-validated Taqman Gene Expression
Assays (Applied Biosystems). Quantitative PCR (qPCR) reactions were performed
in 384-well plates using 1.5 ml of cDNA samples (5–25 ng), 5 ml of the TaqMan Fast
Universal PCR Master Mix (Applied Biosystems), 0.5 ml of the TaqMan Gene
Expression Assay (20X) and 3 ml of water in a ﬁnal volume of 10ml. The assays used
to determine target gene expression levels were designed using the Universal Probe
Library from Roche (www.universalprobelibrary.com). qPCR reactions for target
genes were performed in 384-well plates using 1.5 ml of cDNA samples (5–25 ng),
5 ml of the TaqMan Fast Universal PCR Master Mix (Applied Biosystems), 2 mM of
each primer and 1 mM of UPL probe in a ﬁnal volume of 10 ml. Ampliﬁcation levels
were detected using the ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) programmed to run at 95 C for 3min before starting 40 cycles of 5 s at
95 C and 30 s at 60 C. The reactions were run in triplicate and the quantiﬁcation
performed using average Cts values. The DDCT method was used to determine
relative quantiﬁcation of target genes. The primers used for RT–qPCR (qPCR with
reverse transcription) are listed in Supplementary Table 2.
2-Hydroxyglutarate IC50 determination. The potency of 2-hydroxyglutarate for
KDM4A inhibition was determined by RapidFire Mass Spectrometry61 and as
previously described62. Brieﬂy, 25ml of recombinant human KDM4A (400 nM) was
pre-incubated with 2-hydroxyglutarate during 15min before starting the reaction
by adding 25ml of substrate mix (200 mM L-ascorbic acid, 20mM Fe2þ , 20mM
H3K9(me3) peptide and 20mM 2-oxoglutarate). The enzymatic reaction was
stopped after 50min with 5 ml of 10% formic acid, then the reaction mixture
was transferred to a RapidFire RF360 sampling robot. The samples were applied
onto a C4 Solid Phase Extraction (SPE) cartridge by aspiration under vacuum.
Non-volatile buffer components were removed from the C4 SPE by an aqueous
wash step (0.1% formic acid in water). Then, the peptide was eluted from the C4
SPE onto an Agilent 6530 Q-TOF by an organic wash step (85% acetonitrile in
water, 0.1% formic acid). Peak area data for the substrate and the product methyl
marks were extracted from ion chromatograms and integrated using RapidFire
Integrator software. The percentage of demethylation was calculated using
Microsoft Excel software, and IC50 curves were generated by GraphPad Prism.
Protein stability assay. For half-life measurements, HeLa cells were starved for
24 h and pre-treated with 100mgml 1 cycloheximide and 40 mgml 1 chlor-
amphenicol 1 h before serum addition (10%). The cells were harvested at indicated
time periods and whole cell lysates blotted. The protein levels were normalized to
tubulin and quantiﬁed using ImageJ.
Immunohistochemical stainings of astrocytomas. Diffuse astrocytomas with
IDH1R132H mutation (n¼ 3) or wild-type IDH1/2 (n¼ 3) were processed for
immunohistochemistry. IDH1/2 wild-type status was conﬁrmed by Sanger
sequencing. Four-micrometre thick sections were cut from the selected formalin
parafﬁn embedded specimens and stained using a Benchmark XT immunostainer
(Ventana). The Ventana staining protocol included a pretreatment with Cell
Conditioner 1 for 40min, followed by incubation with the primary antibodies at
37 C for 60min. All the antibodies were diluted in the Ventana dilution buffer as
followed: p-S6S240/244 (D68F8, Cell Signaling Technology, 1:1,000); p-AKT1T308
(Novus Biologicals, 1:30). Incubation was followed by detection using Optiview
DAB IHC detection kit (Ventana).
Reproducibility of experiments. Representative ﬁgures were repeated as follows.
Figs 1d,g; 2b,f and 3g,h and Supplementary Fig. 3g were reproduced at least four
times. Figs 1b,c; 3b,f and 4a,b,g,i and Supplementary Figs 1b–d,k; 2b,c,e; 3a,c; 4a,b;
5a,c,g,h,i were repeated three times. Figs 1h and 2c,e, Figs 3a,c and 4d–f,h and
Supplementary Figs 1a,g–i,l; 2d; 3b,d,i; 5e,f were reproduced twice.
Data availability. The TCGA data referenced in this study are available in a public
repository from the TCGA website (http://cancergenome.nih.gov). The authors
declare that all the other data supporting the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles, and from the corre-
sponding authors upon reasonable request.
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